Dr. Patton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Cannon Dr
1120F Lincoln Tower
Columbus, OH 43210Phone+1 614-814-0146
Summary
- John Patton, MD, is a hematologist specializing in hematologic oncology, based in Columbus, OH. He completed his medical education at Ohio State University College of Medicine in 2020. He went on to complete his residency in Internal Medicine from 2020 to 2022 and is currently finishing his fellowship in Hematology and Medical Oncology at Ohio State University Hospital, expected to finish in 2025. He holds a PhD in Cancer Immunology obtained in 2016 from the same institution. Dr. Patton has contributed to notable publications, including studies on B cell receptor signaling in chronic lymphocytic leukemia, the Epstein-Barr virus, and lymphoproliferative diseases. His work has been recognized and cited multiple times in the scientific community.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2022 - 2025- Ohio State University HospitalResidency, Internal Medicine, 2020 - 2022
- Ohio State University College of MedicineClass of 2020
The Ohio State University PhD, Cancer Immunology , 2012 - 2016
Certifications & Licensure
OH State Medical License 2022 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Glucarpidase for Treatment of High-Dose Methotrexate Toxicity.Shruti Gupta, Sarah Allison Kaunfer, Kevin L Chen, Julie-Alexia Dias, Anitha Vijayan
Blood. 2025-01-06 - 2 citationsTargeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.John T Patton, Jennifer A Woyach
Seminars in Hematology. 2024-04-01 - 12 citationsComplete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and DexamethasoneJames P Dugan, Bradley M. Haverkos, Linda Villagomez, Ludmila Katherine Martin, Mark E. Lustberg
Clinical Cancer Research. 2018-07-15
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
